Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance

Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance

CRISPR-Cas9 genome engineering has revolutionised high-throughput functional genomic screens. However, recent work has raised concerns regarding the performance of CRISPR-Cas9 screens using TP53 wild-type human cells due to a p53-mediated DNA damage response (DDR) limiting the efficiency of generati...

Full description

Bibliographic Details
Main Authors:	Anne Ramsay Bowden, David A Morales-Juarez, Matylda Sczaniecka-Clift, Maria Martin Agudo, Natalia Lukashchuk, John Christopher Thomas, Stephen P Jackson
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2020-05-01
Series:	eLife
Subjects:	CRISPR screening TP53 DNA damage response
Online Access:	https://elifesciences.org/articles/55325

Similar Items

Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library
by: Yuanzhong Wu, et al.
Published: (2020-08-01)

Therapeutic Editing of the <i>TP53</i> Gene: Is CRISPR/Cas9 an Option?
by: Regina Mirgayazova, et al.
Published: (2020-06-01)

Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research
by: Kiyoung Eun, et al.
Published: (2019-01-01)

Identification of functional regulatory elements in the human genome using pooled CRISPR screens
by: Samantha M. Borys, et al.
Published: (2020-01-01)

Efficient Screening of CRISPR/Cas9-Induced Events in Drosophila Using a Co-CRISPR Strategy
by: Nanci S. Kane, et al.
Published: (2017-01-01)

Identification of Essential Genes in Hepatocellular Carcinomas using CRISPR Screening
by: Sheel, Ankur
Published: (2019)

The TP53 fertility network
by: Diego d'Avila Paskulin, et al.
Published: (2012-01-01)

A benchmark of algorithms for the analysis of pooled CRISPR screens
by: Sunil Bodapati, et al.
Published: (2020-03-01)

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
by: Ana B. Herrero, et al.
Published: (2016-11-01)

Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
by: Ava Kwong, et al.
Published: (2020-11-01)

Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening
by: Ning Sun, et al.
Published: (2019-03-01)

Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy
by: Colleen K. Spees, et al.
Published: (2015-03-01)

Multiplex CRISPR/Cas screen in regenerating haploid limbs of chimeric Axolotls
by: Lucas D Sanor, et al.
Published: (2020-01-01)

Polimorfismos do gene TP53 no linfoma de Hodgkin
by: Daniel de AraÃjo Viana
Published: (2007)

Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
by: Fei Zhang, et al.
Published: (2019-06-01)

Extensible combinatorial CRISPR screening in mammalian cells
by: Peng Zhou, et al.
Published: (2021-03-01)

Application of CRISPR-Cas9 technology in the screening of tumor resistance genes: A review
by: Jie Zhang, et al.
Published: (2021-06-01)

TP53 GENE MUTATIONS – FROM GUARDIAN OF THE GENOME TO ONCOGENE
by: Petar Babović, et al.
Published: (2010-03-01)

Tumor protein 53-induced nuclear protein 1 (TP53INP1) enhances p53 function and represses tumorigenesis
by: Jeyran eShahbazi, et al.
Published: (2013-05-01)

Chemical-genetic CRISPR-Cas9 screens in human cells using a pathway-specific library
by: Frances V. Hundley, et al.
Published: (2021-09-01)

VISPR-online: a web-based interactive tool to visualize CRISPR screening experiments
by: Yingbo Cui, et al.
Published: (2021-06-01)

CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens
by: Timothy P. Daley, et al.
Published: (2018-10-01)

Insight of Tp53 Mutations and their effect on Protein in Different Feline and Canine Neoplasms
by: Rashid Saif, et al.
Published: (2016-02-01)

Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
by: Scott Bang, et al.
Published: (2019-12-01)

Case Report: Identification of a Novel Pathogenic Germline TP53 Variant in a Family With Li–Fraumeni Syndrome
by: Francesco Paduano, et al.
Published: (2021-09-01)

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
by: Miguel Quijada‐Álamo, et al.
Published: (2021-02-01)

Polimorfismo do gene tp53 no códon 72 em pacientes com suspeita de LMC Codon 72 polymorphism of the TP53 gene in patients suspected to have CML
by: Camila S. Hamú, et al.
Published: (2007-12-01)

TP53-Deficient Angiosarcoma Expression Profiling in Rat Model
by: Urszula Smyczyńska, et al.
Published: (2020-06-01)

LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53
by: Shaoxian Liu, et al.
Published: (2018-07-01)

The CRISPR-Cas system
by: Stens, Cassandra, et al.
Published: (2020)

Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens
by: Traver Hart, et al.
Published: (2017-08-01)

Création d'un système rapporteur pour l'étude de mutations de p53
by: Parrot, Camila
Published: (2016)

Mutant p53 as a Regulator and Target of Autophagy
by: Yong Shi, et al.
Published: (2021-02-01)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
by: Pavla Brachova, et al.
Published: (2013-09-01)

Mapping of TP53 protein network using cytoscape software
by: Asita Elengoe, et al.
Published: (2018-12-01)

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
by: Paola Monti, et al.
Published: (2020-10-01)

Master Regulators and Cofactors of Human Neuronal Cell Fate Specification Identified by CRISPR Gene Activation Screens
by: Joshua B. Black, et al.
Published: (2020-12-01)

Application of CRISPR-Cas9 Based Genome-Wide Screening Approaches to Study Cellular Signalling Mechanisms
by: Sumana Sharma, et al.
Published: (2018-03-01)

TP53 and PTEN as driver mutations in Zenker's carcinoma—a clinical presentation
by: Zsanett Noel, et al.
Published: (2020-12-01)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
by: Hao Sun, et al.
Published: (2020-10-01)